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SocietyIn 2005, several of the authors wrote an editorial entitled
‘‘Clearing the Air’’ on coxibs and NSAIDs1. Of particular im-
port was a concern regarding cardiovascular (CV) risk of
these agents. At that time, in 2005, it was already noted
that the potential CV risks attributed to the coxibs might
be shared by other NSAIDs. In the United States, all mar-
keted prescription NSAIDs, both nonselective and COX-2
selective were required to revise their labeling by the
Food and Drug Administration (FDA) to include a boxed
warning highlighting the potential for increased CV events
and gastrointestinal (GI) bleeding. In addition, the FDA re-
quested manufacturers of nonprescription, over-the-counter
NSAIDs to include more speciﬁc information on potential
CV and GI risks. Given that, in the US, an estimated 17 mil-
lion individuals are using NSAIDs daily, and that 60 million
prescriptions for various forms of NSAIDs are written each
year, the status of these agents in the management of
pain and inﬂammation is of particular interest. In the Euro-
pean Union, the European Agency for the Evaluation of
Medicinal Products (EMEA) released a Public Statement
summarizing its review of the COX-2 inhibitor class and
noted that they were ‘‘contraindicated in patients with ische-
mic heart disease or stroke’’ and that ‘‘prescribers [should]
exercise caution when prescribing COX-2 inhibitors for pa-
tients with risk factors for heart disease, such as hyperten-
sion, hyperlipidemia, diabetes and smoking, as well as for
patients with peripheral arterial disease’’ (EMEA Public
Statement: London, 17 February 2005).
The importance of osteoarthritis (OA) as an international
clinical problem prompted a workshop organized by the
Osteoarthritis Research Society International (OARSI) and
the International COX-2 Study Group that was held on
March 24e25, 2007. Meeting of the International COX-2
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from individuals with multiple perspectives enriching the
base of information. Of particular interest for review was
the confusion regarding utility of NSAIDs and coxibs in
the treatment of chronic painful and inﬂammatory condi-
tions. In that there are no therapies without inherent risk
to some patients, it is critical to understand the impact of
that potential risk in the context of what clinical improve-
ments can be expected by exposure to the therapy. The dif-
ﬁculty in measuring competing risks vs beneﬁt continues to
be challenging. The availability of a large amount of addi-
tional information related to NSAIDs and coxibs, both as
to efﬁcacy and adverse events, suggested that it might be
worthwhile reviewing the current status of these agents
and their use, particularly as they apply to OA management.
This editorial reviews ‘‘what we knew then’’ and, more im-
portantly, ‘‘what we know now’’.
Efﬁcacy comparisons
A systematic review of randomized controlled trials of
non-opioid analgesics, nonselective NSAIDs (NS NSAIDs)
and/or coxibs in the treatment of OA published up to July
2005 was released by the US Agency for Healthcare
Research and Quality (AHRQ) in 20062. This review con-
cluded that NSAIDs, including coxibs, were superior to acet-
aminophen for reducing pain and improving function in
patients with OA, and that there were no clinically signiﬁcant
differences in efﬁcacy between the various non-aspirin NS
NSAIDs and coxibs when used in comparable doses. Sev-
eral additional studies and a review published after July
2005 have demonstrated that the COX-2 selective NSAIDs
etoricoxib and lumiracoxib have similar efﬁcacy to NS
NSAIDs and to celecoxib for the treatment of OA3e5. Choice
of a NS NSAID or a coxib in the individual patient with OA is
predicated more on differences in safety and cost rather
than efﬁcacy. Given the lack of controversy as to any clini-
cally important differences in efﬁcacy between these types
of NSAIDs, this discussion will concentrate on issues of
adverse event comparisons.49
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GI ADVERSE EVENTS
The FDA has estimated a general risk of 2e4% per year
for NS NSAID-induced symptomatic gastroduodenal ulcer
and/or its complications, which corresponds to the com-
bined endpoint of perforations, symptomatic ulcers and
bleeds (PUBs) in outcome studies. Several meta-analyses
showed a relative risk (RR) of serious adverse GI effects
in persons who were current users of NS NSAIDs to be
three-to-four times that of non-users in the general popula-
tion2,6e11. The COX-2 selective (COX-1 sparing) inhibitors
are associated with a reduced incidence of symptomatic
and complicated ulcers as demonstrated in several large
outcome trials. In the Celecoxib Long-term Arthritis Safety
Study (CLASS) trial, the incidence of symptomatic and com-
plicated ulcers was statistically signiﬁcantly lower in the cel-
ecoxib-treated group compared with the combined
ibuprofen and diclofenac group at 6 months (www.fda.
gov/ohrms/dockets/ac/01/transcripts/3677t1_01.pdf)12. In
the Vioxx Gastrointestinal Outcomes Research (VIGOR)
trial, signiﬁcantly fewer symptomatic and complicated ulcers
occurred in rheumatoid arthritis (RA) patients randomized to
rofecoxib as compared to naproxen13. In the Therapeutic
Arthritis Research and Gastrointestinal Event Trial (TAR-
GET), OA patients randomized to lumiracoxib, a COX-2 se-
lective inhibitor approved in Europe, Canada, Latin
American and Asian countries, but not yet available in the
US, had a signiﬁcantly lower incidence of symptomatic
and complicated ulcers compared to patients randomized
to either naproxen 500 mg twice daily or ibuprofen
2400 mg daily14. In the Multinational Etoricoxib and Diclofe-
nac Arthritis Long-term (MEDAL) program, patients random-
ized to etoricoxib, another coxib approved in Europe, Latin
American and Asian countries but not available in the US,
had a signiﬁcantly lower incidence of symptomatic but not
complicated upper GI events compared to patients random-
ized to diclofenac15. In this latter study, there was no evi-
dence of effect modiﬁcation by concomitant use of either
low-dose aspirin or proton pump inhibitors (PPIs); indeed,
the beneﬁts of etoricoxib were preserved in pre-speciﬁed
subgroup analyses.
Of particular interest is the issue of GI risks associated
with combining aspirin with selective or NS NSAIDs.
Endoscopic studies in patients taking aspirin at a dose of
325 mg/day demonstrated an increased risk for gastric
ulcers and erosions (27.3%) when naproxen was added,
with signiﬁcantly fewer ulcers/erosions associated with
a celecoxib/aspirin combination (18.7%)16. In patients tak-
ing 81 mg of aspirin per day, endoscopic pathologic ﬁndings
with celecoxib/aspirin (7%) were diminished as compared to
the higher dose aspirin ﬁndings but remained high (25.3%)
with naproxen17. It is unclear, however, how these endo-
scopic results translate into clinically relevant outcomes.
In the CLASS trial, there was no evidence of a statistically
signiﬁcant reduction in clinical or complicated ulcers in the
celecoxib-treated patients in the subgroup that received
low-dose aspirin; however, there were relatively few pa-
tients on concomitant aspirin in the various arms of the trial
(21% of the patient population)12. In TARGET, while the
incidence of complicated upper GI events was numerically
reduced by 29% among patients randomized to lumiracoxib
in the subgroup that received low-dose aspirin, this did not
reach statistical signiﬁcance14. However, since neither the
CLASS nor the TARGET study was powered to detect the
beneﬁcial upper GI effects of celecoxib and lumiracoxib,respectively, in the subgroup receiving aspirin co-adminis-
tration, a GI protective effect in the presence of aspirin of
coxibs cannot be excluded. Indeed, Laine and colleagues15
reported that the rate of uncomplicated upper GI clinical
events was signiﬁcantly lower with etoricoxib than with
diclofenac even in the presence of aspirin in the MEDAL
trial that enrolled approximately 34,000 patients (hazard
ratio¼ 0.67 [95% conﬁdence intervals (CIs): 0.47, 0.96]).
The lack of a signiﬁcant reduction in the incidence of com-
plicated events, primarily upper GI bleeding, may be due to
the antiplatelet effects of low-dose aspirin.
Most physicians agree that coxibs are indicated in pa-
tients who have a high risk GI history, including a past his-
tory of upper GI bleeding related to ulcers, past history of
ulcers with recurrent ulcer symptoms, those receiving con-
comitant anticoagulant and/or glucocorticoid therapy, and
in those with other risk factors including aging and presence
of comorbid conditions, and that their use in low-risk pa-
tients or for acute pain is less likely indicated except for peri-
operative administration. It should be noted that even in
low-risk patients, the upper GI toxicity of coxibs is lower
than that of NS NSAIDs. Since there are considerably
more people in the low-risk category, the use of coxibs
with their superior GI toxicity proﬁle likely would result in di-
minished overall adverse events. Cost-effectiveness analy-
ses support their use in the patient group at high risk for
serious upper GI complications where the use of coxibs is
cost effective, balancing their use vs NS NSAIDs in combi-
nation with either misoprostol or a PPI18,19.
Few studies have compared the GI safety of coxibs to the
combination of a NS NSAID plus a PPI. A randomized trial
in a very speciﬁc population (RA patients with a recent his-
tory of upper GI bleeding) failed to demonstrate a statisti-
cally signiﬁcant difference between treatment with
celecoxib plus placebo vs 150 mg of diclofenac plus
20 mg omeprazole daily for 6 months, with a re-bleed rate
over 6 months of approximately 6%20. However, two recent
trials have suggested that a coxib plus a PPI may provide
greater gastroprotection than a traditional NSAID plus
a PPI. For example, a subsequent study by Chan et al.21
demonstrated that in a high risk population, celecoxib plus
esomeprazole was more effective than celecoxib alone in
preventing recurrent ulcer bleeding: the 13-month cumula-
tive incidence was 0% in the celecoxibþ esomeprazole
group vs 8.9% in the celecoxib alone controls (95% CI
difference: 4.1e13.7; P¼ 0.0004). In the MEDAL program,
described above, the reduction in uncomplicated events
with etoricoxib vs diclofenac was maintained in the sub-
group of patients treated with PPIs15.
CV ADVERSE EVENTS
As noted in our previous editorial, the incidence of myo-
cardial infarction (MI) in RA patients enrolled in the VIGOR
trial was signiﬁcantly higher with rofecoxib 50 mg/day than
that seen with patients receiving naproxen 500 mg twice
daily13. Explanations for the observation of the increased
rate of non-fatal acute MIs with rofecoxib as compared to
naproxen included, for example, (1) all patients in the study
group had RA, a disease known to be associated with
a higher CV risk; (2) low-dose aspirin was not allowed;
and (3) a possible CV prophylactic effect of naproxen simi-
lar to that seen with aspirin because of an antiplatelet effect
due to inhibition of platelet-derived thromboxane during the
dosing interval. Alternatively, it was suggested that rofe-
coxib might induce a prothrombotic state related to an
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clin22,23. Inhibiting prostacyclin could result in lessening of
vasodilatation as well as diminished inhibition of platelet ag-
gregation without a counterbalanced inhibition of thrombox-
ane A2 in the at-risk patient. Other important issues may
contribute to the increased CV risk including varying drug
effects on nitric oxide (NO), effects on mean blood pres-
sure, salt and water balance, and differential membrane
effects of various therapies.
A meta-analysis of the celecoxib database did not dem-
onstrate an increased CV risk24; however, the trials were
usually 6 months or less in duration and the number of
events was low. The relationship of rofecoxib and celecoxib
use to increased CV events was observed in placebo-
controlled trials for polyp prevention in patients with colonic
polyps, and, in the case of celecoxib was observed at
higher than clinically recommended therapeutic doses for
OA25e27. An increased frequency of cardiac events was
also noted in patients undergoing coronary bypass surgery
receiving perioperative administration of valdecoxib and
parecoxib28. In TARGET14, no statistically signiﬁcant in-
creased risk for CV events was noted when lumiracoxib
was compared to ibuprofen and naproxen; however, there
was a numerically higher incidence of CV events in the lu-
miracoxib group compared to naproxen, although the over-
all incidence of events was low. A recent post hoc analysis
of patients at high risk for CV events studied in TARGET
showed that participants who were randomized to ibuprofen
and took concomitant low-dose acetylsalicylic acid (ASA)
had signiﬁcantly more CV primary events and congestive
heart failure than those randomized to lumiracoxib (2.14%
vs 0.25%, P¼ 0.038), suggesting that ibuprofen may inter-
fere with the cardioprotective effects of low-dose aspirin29.
Indeed, this result is consistent with experimental data
showing a pharmacodynamic interaction between low-
dose aspirin and ibuprofen and epidemiologic data showing
an increase in mortality in persons with MIs taking ibupro-
fen29e31. Based on these latter data, the FDA issued a warn-
ing against the use of ibuprofen in patients taking low-dose
aspirin for secondary prophylaxis after a CV thrombotic
event.
In the MEDAL program, there was no difference in the
rate of CV thrombotic events between patients randomized
to etoricoxib or diclofenac; patients were stratiﬁed on the
use of low-dose aspirin and participating investigators
were encouraged to administer aspirin prophylaxis as indi-
cated for secondary prevention32. There was, however,
a signiﬁcant increase in the number of etoricoxib-treated pa-
tients who withdrew from the trial due to congestive heart
failure and increased hypertension.
In 2006, Kearney and colleagues33 published a system-
atic review and meta-analysis of 138 randomized placebo
or active-comparator controlled trials of coxibs to estimate
the increased risk for CV thrombotic events among patients
treated with coxibs. This study found a 42% increased risk
(95% CI: 1.18, 1.78) for the combined Anti-Platelet Trialist
Collaboration (APTC) endpoint among patients randomized
to a coxib as compared to placebo: absolute rates were
1.2 per 100 person-years as compared to 0.9 per 100 per-
son-years corresponding to an excess rate of 0.3 events
per 100 person-years and a number needed to harm of
333. The increased risk was primarily attributed to an ap-
proximate twofold increase in the rate of non-fatal MI and
a 50% increase in the risk of vascular death; there was
no signiﬁcant difference in the risk of stroke. Among studies
that compared coxibs to NSAIDs, there was no evidence of
a difference in the risk for APTC events among patientsrandomized to a coxib as compared to non-naproxen NS
NSAIDs, primarily ibuprofen and diclofenac, while there
was a signiﬁcantly increased risk for APTC events among
patients randomized to a coxib as compared to naproxen.
Again, this increased risk was primarily attributed to an in-
crease in the risk of non-fatal MI and, less so, vascular
death, without a signiﬁcant excess in risk of stroke. While
the authors failed to demonstrate heterogeneity in risk
among the different coxibs, there was evidence of a dosee
response relationship for celecoxib with increased risk for
APTC events associated with higher doses (e.g., 200 mg
and 400 mg twice daily as compared to 200 mg once daily).
In addition to randomized clinical trials, epidemiologic
studies have evaluated the RR for CV events with coxibs
and NS NSAIDs. Two large observational cohort studies
demonstrated increased risk for CV events with rofecoxib
used in doses greater than 25 mg daily34,35. In a third cohort
study36, doses of rofecoxib greater than 25 mg/day were
associated with more than a threefold higher incidence of
acute MI and sudden cardiac death compared with NS
NSAIDs. In this analysis of Kaiser Permanente patients,
naproxen was associated with an increased risk of thrombo-
embolic CV events (RR¼ 1.18; 95% CI: 1.04e1.35;
P¼ 0.01), as was indomethacin (RR¼ 1.33; 95% CI:
1.09e1.63; P¼ .005). In another study, Singh and col-
leagues demonstrated increased CV risk in patients being
treated with diclofenac, indomethacin, sulindac and melox-
icam, with decreasing rates of CV risk for other selective
and NS NSAIDs37. Since the publication of the previous ed-
itorial in 20051, two systematic reviews of observational
studies of the relationship of NSAIDs and coxibs with CV
thrombotic events have been published38,39. The former in-
cluded 16 studies that examined the association of coxib or
NSAID use and MI; the latter included 23 studies that exam-
ined the association of coxib or NSAID use and CV events,
primarily MI and vascular death. In both analyses, rofecoxib
use was associated with a statistically signiﬁcant increased
risk of a CV event in a doseeresponse relationship (i.e., the
risk was greater for users of doses greater than 25 mg/day
than for those using doses of 25 mg or less per day) while
celecoxib use was not associated with a statistically signif-
icant increased risk of a CV event. The latter ﬁnding is con-
sistent with that from the meta-analysis of Kearney and
colleagues (vide supra) in suggesting that celecoxib at
a dose of 200 mg/day is not associated with a signiﬁcant in-
crease in risk for MI or other CV thrombotic event. Both
meta-analyses of observational studies found no evidence
of increased risk for MI or other CV events among users
of naproxen, and evidence of a signiﬁcant increased risk
for MI or other CV events among users of diclofenac; there
were, however, conﬂicting results for ibuprofen. The former
analysis reported an increased risk associated with the use
of ibuprofen (summary RR¼ 1.07, 95% CI: 1.02, 1.12),
while the latter failed to ﬁnd a signiﬁcant increased risk as-
sociated with the use of ibuprofen (summary RR¼ 1.07,
95% CI: 0.97, 1.18); note that the point estimates in the
two studies were identical.
The mechanisms whereby both selective and NS
NSAIDs may contribute to adverse CV events may be mul-
tiple in origin. The hypothesis whereby there is an imbal-
ance of prostacyclin and thromboxane inhibition may play
a signiﬁcant role in part in the etiology of these ﬁndings22.
Of import in this regard is the demonstration that the maxi-
mal biosynthetic capacity of human platelet production of
thromboxane A2 when challenged in vitro by thrombin ex-
ceeds the actual rate of thromboxane A2 synthesis in vivo
by several 1000-folds40. This impressive ability of the
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may explain, at least in part, the unusual requirement for vir-
tually complete suppression of platelet COX-1 activity in or-
der for pharmacologic inhibition to translate into functional
platelet impairment. In addition, TBXA2 inhibition at a level
of 95% or more is required before a demonstrable effect on
platelet aggregation can be seen. Of interest is the ﬁnding
that, however, a protective role for aspirin administered at
the same time as coxibs has not appeared to consistently
diminish CV risk26,28,33,36,38,39,41. Accordingly, other causes
to explain increased CV risk have been considered. Both
nonselective and selective NSAIDs may be associated
with increased blood pressure in individuals receiving anti-
hypertensive therapy, particularly diuretics and angiotensin
converting enzyme inhibitors42,43. This effect may at times
be dramatically obvious with raises of 20 mm or more asso-
ciated with NSAID administration. Studies have demon-
strated mean increases in systolic blood pressure of
4e6 mm, an elevation sufﬁcient to result in a clinically im-
portant increase in total stroke occurrence and coronary
heart disease44. Differences amongst the nonselective
and selective NSAIDs in their propensity to induce hyper-
tensive changes may account for some of the differences
seen clinically in the CV event proﬁle. Differences in risk
may be related to drug half-life, as well as the level of pro-
tein binding. Agents with a long half-life will have a more
pronounced, prolonged effect on blood pressure; similarly,
agents which are less tightly protein bound may exert free
drug activity at a greater level and for longer periods of
time than those which have almost complete protein
binding.
Other factors such as NO production by endothelial cells
may play a role in the CV event proﬁle45e47. NO reduces
proliferation and leukocyte migration with an effect on ves-
sel inﬂammation. Decreased NO production has been impli-
cated in the pathogenesis of CV disease. NO effects may
potentially outweigh the effects of prostacyclin and throm-
boxane. The pro-oxidant effects as well as effects on vaso-
constriction and blood pressure increase have been
studied48. There are differential effects of these drugs on
membranes and on NO. In addition to the factors noted
above, the effect of pain as an important CV risk factor is
not often appreciated. Pain increases stress and sympa-
thetic nerve responses with increased heart rate and ele-
vated blood pressure, aggravating any CV risk resulting
from other mechanisms.
Acetaminophen has been recommended as an initial
pharmacologic therapy for OA patients with mild to moderate
pain by the American College of Rheumatology, the Ameri-
can Pain Society and the European League of Associations
of Rheumatology49e51. Of concern in this regard are recent
studies demonstrating that acetaminophen, when adminis-
tered more than 15 days a month in women increases the
RR of acute MI, sudden cardiac death and stroke by approx-
imately 50%, especially in the individuals who are smokers,
similar to the effects of the NS NSAIDs within the same
database52. This increased CV risk may be associated
with increased hypertension reported in chronic users of
acetaminophen in observational studies53,54. Even at low
doses, acetaminophen was shown capable of inhibiting
prostacyclin without affecting thromboxane55, the imbalance
paradigm seen with coxibs and NSAIDs. Given the greater
efﬁcacy of NSAIDs and coxibs as compared to acetamino-
phen (vide supra) and the apparent similarity in CV risk in ob-
servational studies, the beneﬁts of acetaminophen use may
require renewed scrutiny.A major issue regarding CV thrombotic events relates to
the administration of aspirin concomitantly with NSAIDs.
Evidence has shown that administration of NSAIDs such
as ibuprofen, naproxen and indomethacin may be associ-
ated with attenuation of aspirin prophylaxis of CV
events29,30,56e58. Aspirin irreversibly acetylates the serine
530 site on the COX-1 enzyme in the platelet. In the pres-
ence of ibuprofen which blocks the binding site, the aspirin
effect on the platelet at this same site will be abrogated,
putting the patient at increased risk associated with loss
of aspirin protection. Blockage of the aspirin-binding site
is not seen with simultaneous administration of aspirin
and coxibs or with diclofenac, due to differences in binding
to COX-1 by these agents. It has been suggested that if the
aspirin is taken several hours before the NS NSAIDs, that
the aspirin effect will not be diluted. This may be true for
single or occasional multiple doses of NSAIDs but, in the
presence of continued therapy steady state leading to a
constant low level of NSAID, inhibition of the aspirin effect
is likely. Although in vitro data demonstrate this interaction
in deﬁnitive fashion, clinical studies demonstrating increased
CV event risk in patients receiving a combination of aspirin
and ibuprofen have been inconsistent (vide supra). Never-
theless, the risk that a patient receiving ibuprofen will
have effective aspirin prophylaxis inhibited is of signiﬁcant
concern; indeed, ibuprofen has been relabeled by the
FDA to reﬂect this caution. It is possible that different
NSAIDs will have different effects in this regard. For exam-
ple, naproxen, given at a dose of 500 mg every 12 h may be
an effective inhibitor of platelet aggregation per se in some
patients due to its long half-life; recent data suggest that the
vast majority of subjects maintains inhibition of thrombox-
ane production at greater than 95% even at the end of
a 12-h dosing interval. Nonetheless, as long-term clinical
studies demonstrating prophylaxis equal to that of aspirin
have not been performed, naproxen cannot be recommen-
ded as an antiplatelet agent in clinical practice. In addition,
there may be differences in the ability of various NSAIDs to
bind to the aspirin-binding site leading to clinical differences
in NSAID and aspirin interaction. Paradoxically, individuals
taking low, over-the-counter doses of NSAIDs may be at
higher risk of inhibiting the aspirin platelet protective effect
than NSAIDs given at full doses since, at low doses, effec-
tive inhibition of thromboxane might be less likely than that
seen with higher doses.
So where do we stand
We have a great deal more information than 2 years ago
but, paradoxically, this new information has made our life as
physicians treating OA more complex. It seems that ‘‘the
more we know, the more we realize we need to know
more’’. There are some areas in which there is general
agreement. Coxibs appear to be safer with respect to GI
toxicity and tolerance than nonselective NSAIDs. Studies
have demonstrated that up to 40% of GI bleeds associated
with the use of NSAIDs are of lower intestinal origin, occur-
ring in sites distal to the Ligament of Treitz59. The use of
PPIs will decrease upper but not lower GI events. Misopros-
tol is prophylactic with respect to upper, but not necessarily
lower GI bleeding, but has its own GI adverse intolerance
proﬁle. A large outcome study comparing a coxib to the
combination of a NS NSAID plus a PPI would provide im-
portant information of the contribution of lower GI bleeding
to the total adverse GI outcomes.
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respect to all NSAIDs, both selective and nonselective. This
concern, however, does not appear to be equal for all
NSAIDs. For example, rofecoxib, at least in higher doses,
appeared to have a consistently higher CV risk proﬁle
than other coxibs or NS NSAIDs. Naproxen appears to have
a somewhat safer CV proﬁle, possibly related to a more
effective inhibition of platelets, perhaps related to its long
half-life. Celecoxib in a dose of 200 mg once daily appears
to be similarly safer although long-term studies exceeding
12 months would be reassuring (as supported by Preven-
tion of Sporadic Adenomatous Polyps (preSAP) at
400 mg/day)27. In patients receiving low-dose aspirin, the
addition of a NS NSAID agent with its potential to inhibit as-
pirin prophylaxis may be more harmful to the patient than
the CV risk associated with the NSAID alone. In patients re-
ceiving aspirin prophylaxis in the presence of high CV risk
factors, coxib therapy has an advantage of not interfering
with aspirin prophylaxis. The authors note, however, that
use of coxibs is proscribed in patients with high CV risk
factors in countries under EMEA jurisdiction. Moreover,
although more deﬁnitive studies are necessary, the data
do suggest that ibuprofen may interfere with the ASA cardi-
opreventive effect. Indeed, in the patient with both high CV
and GI risk, the ‘‘best’’ option might be to combine low-dose
aspirin with a coxib and a PPI.
Therapeutic judgment requires balancing any increased
CV risk with the not inconsequential risk of NS NSAIDs as-
sociated with GI bleeding. Balancing these various risks is
not easy and requires individualization from patient to pa-
tient. Human nature being what it is, the thought of having
a heart attack is more frightening to most individuals than
is having a GI bleed; they consider that blood can be re-
placed and the bleeding stopped with resolution of ﬁndings
to the pre-morbid status without necessarily having perma-
nent organ damage. With respect to heart attacks, however,
patients see this in a more threatening light with the poten-
tial for irreversible cardiac damage leading to the develop-
ment of congestive heart failure, an understandable
concern.
Treatment guidelines for the use of analgesic and anti-
inﬂammatory agents in OA have been published by many
organizations including but not limited to the American Col-
lege of Rheumatology, American Pain Society and Euro-
pean League of Associations of Rheumatology48e51; most
have not been updated except for the recent Seventh Cana-
dian Consensus statement60. These guidelines are meant
to provide evidence-based recommendations that will allow
the physician, in concert with the patient, to select the most
appropriate treatment for each patient, balancing safety and
efﬁcacy. There is no one single pathway that is correct for
all patients in all situations! The statement was made sev-
eral years ago that there would be no use for traditional
NS NSAIDs given the advantages of coxibs with respect
to their advantageous GI adverse event proﬁle. The new
ﬁndings related to CV events, however, have led to a re-
evaluation of therapeutic approaches. Given the ﬁnding
that there appears to be a level playing ﬁeld with respect
to CV events for both coxibs and NS NSAIDs except nap-
roxen and perhaps low-dose celecoxib, coxibs with their
combined higher GI safety proﬁle and lack of aspirineplate-
let interaction (not shared by naproxen), may be an advan-
tageous therapeutic approach in many patients.
A recent scientiﬁc statement from the American Heart As-
sociation (AHA) on the treatment of OA is of interest61. This
directive, authored by highly respected cardiologists, pre-
sented an inverted pyramid describing a stepped careapproach to pharmacologic therapy for musculoskeletal
symptoms in patient with known CV disease or with CV
risk factors. These authors suggested acetaminophen, full
doses of aspirin, non-acetylated salicylates or short-term
narcotic analgesics as an initial therapy. Although full doses
of aspirin up to 4 gm or more a day was not uncommon 30
or 40 years ago, the use of aspirin at such dosage levels is
almost nonexistent in today’s practices. The risk of high-
dose aspirin, not only with respect to GI bleeding but also
with respect to the potential for increased hemorrhagic
stroke makes its use untenable. Non-acetylated salicylates
may be a consideration but these tend to be less effective
than commonly used NSAIDs and may take a longer time
to begin to beneﬁt the patient. Historically, the non-acety-
lated salicylates, which unlike aspirin do not acetylate the
COXs, have been considered to be safer with respect to
bleeding and peptic ulcer disease due to their lack of
COX-1 inhibition. However, there are no data which suggest
that non-acetylated salicylates are safer than other NSAIDs
with respect to CV adverse events. It is of concern that the
AHA guidelines, presented as evidence-based scientiﬁc
recommendations, promote these agents as preferred to
NSAIDs and coxibs in patients with CV risk as there is no
evidence to support their long-term safety. It is important
to note that non-acetylated salicylates are COX-1 sparing,
and, in principle, at therapeutic doses should have the
same potential to impart CV complications as other
NSAIDs. We strongly recommend to the AHA that this
non-evidence-based recommendation, together with the
recommendation that high-dose aspirin be administered
alone, be withdrawn as recommendations for ﬁrst line ther-
apy for patients with chronic pain and arthritis.
In the AHA document, coxibs are recommended as a last
therapeutic approach. The authors also suggest that NS
NSAIDs can be differentiated as to CV toxicity on the basis
of in vitro COX-2 to COX-1 inhibition ratios. Data do not ex-
ist at this time that would allow transposition of these ratios
to clinically observed CV events. Indeed, the weight of the
clinical evidence indicates that we cannot differentiate CV
risk among the currently available NSAIDs, except possibly
high-dose naproxen and lower dose celecoxib. Accordingly,
recommendation of the use of NS NSAIDs prior to the use
of COX-2 selective agents lacks clinical support, particularly
in the patient at increased risk for a serious upper GI ad-
verse event. As these authors note, even a relative lack
of COX selectivity does not completely eliminate the risk
of CV events, and, accordingly, all drugs in the NSAID
spectrum require prescription only after thorough consider-
ation of the risk/beneﬁt balance.
Additionally, the AHA statement suggested early use of
opioids more often and before use of NSAIDs in OA pa-
tients. Although short-term use of opioids for severely pain-
ful exacerbations is not unreasonable, use of long-term
opioids is not recommended for chronic non-cancer pain
by either the American Pain Society or the American Acad-
emy of Pain Management. Further, the fact that patients
with OA tend to be older and, accordingly more predisposed
to opioid-related adverse events including constipation,
dizziness, confusion and central nervous system toxicity
related to dysphoria, risk of falls and, consequently, risk of
hip fracture militates against their routine use.
Prospective studies to evaluate CV risk are underway.
The Standard Care Celecoxib Outcome Trial (SCOTT)
has been designed utilizing the so-called Streamline Safety
model study. The trial will identify subjects taken chronic
NSAIDs in the setting of primary care practices, and will ran-
domize consenting subjects to continue to receive standard
854 R. W. Moskowitz et al.: Coxibs and NSAIDscare or celecoxib. Trial medication will be supplied by
prescription; prescribing will be tracked by capturing pre-
scribing data from primary care computer systems. The pri-
mary endpoint will be CV events and upper GI hemorrhage.
This trial is intended to provide data on CV safety using cel-
ecoxib vs standard care NSAIDs in the European Union in-
dicated population. Participants will be free of established
CV disease on entry.
The Prospective Randomized Evaluation of Celecoxib
Integrated Safety vs Ibuprofen Or Naproxen (PRECISION)
Trial has been designed to compare CV and GI events re-
lated to the use of celecoxib, naproxen and ibuprofen in pa-
tients with moderate CV risk. Approximately 20,000 patients
will be evaluated in a trial whose outcome includes MI,
stroke or death. Up to two-thirds of the individuals will be
taking low-dose aspirin prophylaxis; one-third will be non-
users of aspirin. The trial, which will extend for 3 years or
longer, will not have a placeboecontrol group given the dif-
ﬁculty of maintaining individuals in a study for this period of
time without some form of continuous pharmacologic ther-
apy. Accordingly, it may be difﬁcult to evaluate the results
of this investigation in the event that all three agents have
equal number of CV events. Should one of the agents ap-
pear to be superior, one will still not be able to ascertain
whether that agent has more risk than no therapy alone.
All patients will receive a PPI as part of baseline therapy.
Patients recruited in the study will have to have a history
of increased CV risk factors such as hypertension, diabe-
tes, hypercholesterolemia and the like. Daily doses of med-
ication may be varied but should not exceed 400 mg of
celecoxib, 1000 mg of naproxen, or 2400 mg of ibuprofen.
Patients will be instructed to take their medication 2 h or
more after low-dose aspirin. Although, as noted, this study
has inherent problems with respect to lack of a placeboe
control group, as well as the potential for increased risk of
individuals being administered NS NSAIDs which may af-
fect aspirin prophylaxis, the study should provide important
information which will help us address important, often con-
troversial issues.
The OARSI has appointed a Guidelines Committee to de-
ﬁne recommendations for the treatment of OA that would
have international acceptance. These guidelines are based
on a systematic review of the literature delineating evi-
dence-based information covering therapeutic modalities,
which are used in OA treatment. Publication of these guide-
lines is anticipated for late summer or autumn 2007. Al-
though the guidelines have not been ﬁnalized, there is
concurrence that both nonselective and selective NSAIDs
have a major role in the management of OA. Use of any
therapeutic agent needs to be based on effectiveness,
a combination of efﬁcacy and risks, individualized to take
into account the needs of each speciﬁc patient. ‘‘Treatment
paralysis’’ wherein we send the patient out of the ofﬁce in
pain based on risk concerns needs to be avoided to the de-
gree feasible. The importance of evaluation of risk and the
concept of ‘‘First, do no harm’’ should always be uppermost
in the physician’s mind. Accordingly, any agent, when pos-
sible, should be used at the lowest possible dose for the
shortest possible time e this is true not only of NSAIDs
and coxibs, but for any drug being used for any purpose.
Patients in pain experience not only pain but also functional
loss and psychologic stress. Although risks, including both
GI and CV adverse events are not to be considered lightly,
relief of pain with its resultant improved quality of life may
outweigh associated therapeutic risk. Only the patient,
armed with knowledge of the risk/beneﬁt ratio can makethe ﬁnal decisiondnot always an easy one. In medicine, as
in life, the wind is not always at one’s back!
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